Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.25M, -55.1% YoY · Filed Aug 14, 2026
Biolargo, Inc. (BLGO) files with the SEC under industry code 2800, Chemicals & Allied Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.2 million and a net loss of $4.0 million. As of Jun 30, 2026 it held $2.2 million in cash and investments and $1.3 million in total debt.
Revenue
$1.25M
-55.1% vs year-ago quarter
Net income
$-4.00M
-112.5% vs year-ago quarter
Operating cash flow
$-3.06M
-44.3% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
328.73M
+6.4% vs year-ago quarter
Net cash
$900,000
Q2 FY2026
Operating margin
-443.9%
TTM
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- BLGO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westminster, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 880242
- Former names
- NUWAY MEDICAL INC (until Apr 3, 2007); NUWAY ENERGY INC (until Feb 5, 2003); LATIN AMERICAN CASINOS INC (until Feb 15, 2001)
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Ingevity Corp NGVT
- Innospec Inc. IOSP
- Chemours Co CC
- OLIN Corp OLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $617,000 | $1.1M | $2.8M |
| Operating income | -$3.7M | -$3.2M | -$4.0M | -$7.2M | -$1.8M |
| Net income | -$4.0M | -$3.4M | -$4.1M | -$7.2M | -$1.9M |
| Operating cash flow | -$3.1M | -$2.9M | -$1.6M | -$2.8M | -$2.1M |
| Total assets | $6.7M | $8.6M | $8.3M | $9.1M | $12.5M |
| Total liabilities | $9.4M | $8.8M | $6.8M | $5.9M | $6.4M |
| Stockholders' equity | -$1.9M | $1.8M | $4.0M | $6.6M | $8.8M |
| Cash and investments | $2.2M | $4.1M | $3.9M | $4.5M | $3.5M |
| Total debt | $1.3M | $1.4M | $3.5M | $1.6M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 6, 2026 | May 5, 2026 |
All 1000 Biolargo, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.